NI200600094A - Compuesto heterociclicos fusionados - Google Patents

Compuesto heterociclicos fusionados

Info

Publication number
NI200600094A
NI200600094A NI200600094A NI200600094A NI200600094A NI 200600094 A NI200600094 A NI 200600094A NI 200600094 A NI200600094 A NI 200600094A NI 200600094 A NI200600094 A NI 200600094A NI 200600094 A NI200600094 A NI 200600094A
Authority
NI
Nicaragua
Prior art keywords
heterocyclic compound
fused heterocyclic
serotonin
modulators
useful
Prior art date
Application number
NI200600094A
Other languages
English (en)
Spanish (es)
Inventor
Carruthers Nicholas
Chai Wenying
Dvorak Curt
K Kwok Annette
T Liang Jimmy
Mani Neelakandha
Rudolph Dale
Wong Victoria
Deng Xiaohu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34526458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200600094(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI200600094A publication Critical patent/NI200600094A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NI200600094A 2003-09-17 2006-04-20 Compuesto heterociclicos fusionados NI200600094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50452803P 2003-09-17 2003-09-17
US55267304P 2004-03-11 2004-03-11

Publications (1)

Publication Number Publication Date
NI200600094A true NI200600094A (es) 2014-02-25

Family

ID=34526458

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200600094A NI200600094A (es) 2003-09-17 2006-04-20 Compuesto heterociclicos fusionados

Country Status (29)

Country Link
US (5) US7402680B2 (enExample)
EP (1) EP1668014B1 (enExample)
JP (1) JP5069907B2 (enExample)
KR (1) KR101151653B1 (enExample)
CN (1) CN103788089A (enExample)
AR (1) AR047218A1 (enExample)
AT (1) ATE420881T1 (enExample)
AU (1) AU2004283196B2 (enExample)
BR (1) BRPI0414541B8 (enExample)
CA (1) CA2539426C (enExample)
CL (1) CL2009000943A1 (enExample)
CR (1) CR8302A (enExample)
CY (1) CY1109416T1 (enExample)
DE (1) DE602004019118D1 (enExample)
DK (1) DK1668014T3 (enExample)
EA (2) EA200801812A1 (enExample)
EC (1) ECSP066436A (enExample)
ES (1) ES2319539T3 (enExample)
IL (2) IL174283A (enExample)
IS (1) IS2756B (enExample)
MX (1) MXPA06003150A (enExample)
NI (1) NI200600094A (enExample)
NZ (1) NZ545836A (enExample)
PL (1) PL1668014T3 (enExample)
PT (1) PT1668014E (enExample)
SG (1) SG146683A1 (enExample)
SI (1) SI1668014T1 (enExample)
TW (1) TWI345565B (enExample)
WO (1) WO2005040169A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003150A (es) * 2003-09-17 2006-08-31 Johnson & Johnson Compuestos heterociclicos fusionados.
WO2005079845A1 (ja) * 2004-02-20 2005-09-01 Astellas Pharma Inc. 片頭痛予防薬
ES2398694T3 (es) 2004-06-30 2013-03-21 Athersys, Inc. Derivados de azepina sustituidos como moduladores de receptores de serotonina
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080171788A1 (en) * 2005-02-08 2008-07-17 Shinobu Akuzawa Medicament For Irritable Bowel Syndrome
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
KR101353268B1 (ko) * 2005-08-04 2014-02-06 얀센 파마슈티카 엔.브이. 세로토닌 수용체 모듈레이터로서의 피리미딘 화합물
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2617473A1 (en) * 2005-08-08 2007-02-15 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
AU2007207508B2 (en) * 2006-01-19 2011-08-18 Athersys, Inc. Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
CN101479252B (zh) * 2006-05-05 2014-01-29 詹森药业有限公司 用于制备含吡唑的化合物的方法
CN101511833A (zh) * 2006-08-28 2009-08-19 埃科特莱茵药品有限公司 1,4,5,6,7,8-六氢-1,2,5-三氮杂-甘菊环烃衍生物
WO2009058810A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica N.V. Process for the preparation of substituted 2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene derivatives
EP2229361A1 (en) * 2008-01-03 2010-09-22 Allergan, Inc. Tetrahydroindoles having sphingosine-1-phosphate receptor activity
US8829011B2 (en) 2008-10-29 2014-09-09 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
EP2358714B1 (en) 2008-11-18 2012-08-01 F. Hoffmann-La Roche AG Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
US8492374B2 (en) * 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
AU2012244846B2 (en) 2011-04-21 2016-07-07 Basf Se Novel pesticidal pyrazole compounds
AU2011376717A1 (en) 2011-09-14 2014-03-20 Proximagen Limited New enzyme inhibitor compounds
WO2013156318A1 (en) 2012-04-16 2013-10-24 Basf Se Substituted pesticidal pyrazole compounds
ES2800288T3 (es) 2012-06-20 2020-12-29 Basf Se Mezclas plaguicidas que comprenden un compuesto de pirazol
CN104936960B (zh) * 2012-08-16 2016-12-28 詹森药业有限公司 作为n型钙通道阻滞剂的吡咯并吡唑
WO2014063942A1 (en) 2012-10-23 2014-05-01 Basf Se Substituted pesticidal pyrazole compounds
CA2894552A1 (en) 2012-12-21 2014-06-26 Abt Holding Company Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2015055497A1 (en) 2013-10-16 2015-04-23 Basf Se Substituted pesticidal pyrazole compounds
ES2911293T3 (es) * 2014-11-21 2022-05-18 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CA2975997A1 (en) * 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CN105503647A (zh) * 2015-12-10 2016-04-20 苏州昊帆生物科技有限公司 环丙基肼盐酸盐的制备方法
US9951039B2 (en) * 2016-04-08 2018-04-24 The Hong Kong Polytechnic University Pyrimidines for treatment of bacterial infections
KR101917264B1 (ko) * 2016-12-22 2018-11-13 한국과학기술연구원 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2019137995A1 (en) 2018-01-11 2019-07-18 Basf Se Novel pyridazine compounds for controlling invertebrate pests
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2021145655A1 (ko) * 2020-01-13 2021-07-22 압타바이오 주식회사 신규한 피라졸 유도체
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
US3312716A (en) 1964-08-11 1967-04-04 Aldrich Chem Co Inc 4-hydroxy-3-pyrrolidinemethanols
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1484140A (en) 1974-04-24 1977-08-24 Wyeth John & Brother Ltd Pyrrolopyridine derivatives
US3969355A (en) 1974-11-01 1976-07-13 Morton-Norwich Products, Inc. 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4857330A (en) 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
JPH03148265A (ja) 1989-11-01 1991-06-25 Sumitomo Chem Co Ltd ５，７―ジフェニル―４，６―ジアザインダン誘導体、その製造法およびそれを有効成分とする除草剤
US5137890A (en) * 1990-02-14 1992-08-11 Ortho Pharmaceutical Corporation 4-phenyl tetrahydropyrido(4,3-d)pyrimidines
US5053508A (en) 1990-03-09 1991-10-01 American Home Products Corporation Fused heterotricyclic imides with psychotropic activity and intermedrates thereof
US5648352A (en) 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
WO1994014777A1 (en) 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US6677310B1 (en) 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US5843912A (en) 1994-07-06 1998-12-01 Universy Of Maryland Ring-expanded nucleosides and nucleotides
US5405848A (en) 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
WO1995029909A1 (en) 1994-04-29 1995-11-09 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
AU5317996A (en) 1995-04-18 1996-11-07 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
EP0883613A1 (en) 1996-02-09 1998-12-16 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
TW470745B (en) 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6025367A (en) 1996-06-25 2000-02-15 Smithkline Beecham Plc Sulfonamide derivatives as 5HT7 receptor antagonists
JP4076234B2 (ja) 1996-06-28 2008-04-16 明治製菓株式会社 テトラヒドロベンズインドール化合物
GB9700899D0 (en) 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
AU6290998A (en) 1997-03-07 1998-09-29 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
EP0905136A1 (en) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
US5951518A (en) 1997-10-31 1999-09-14 Teleflex, Incorporated Introducing device with flared sheath end
AU1558899A (en) 1997-11-10 1999-05-31 F. Hoffmann-La Roche Ag Isoquinoline derivatives for use against cns disorders
WO1999054303A1 (en) 1998-04-22 1999-10-28 Meiji Seika Kaisha, Ltd. Optically active tetrahydrobenzindole derivatives
WO1999061027A1 (en) 1998-05-22 1999-12-02 Eli Lilly And Company Combination therapy for treatment of refractory depression
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
WO2000024399A1 (en) 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6245785B1 (en) 1998-11-30 2001-06-12 Warner Lambert Company Dissolution of triprolidine hydrochloride
GB9828004D0 (en) 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
GB9906624D0 (en) 1999-03-23 1999-05-19 Smithkline Beecham Plc Novel compounds
CZ20013465A3 (cs) 1999-04-01 2002-10-16 Pfizer Products Inc. Aminopyrimidiny jako inhibitory sorbitoldehydrogenasy
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
CN1238343C (zh) 1999-09-09 2006-01-25 组合化学工业株式会社 嘧啶衍生物及含有该衍生物的除草剂
WO2001029029A1 (en) 1999-10-18 2001-04-26 Smithkline Beecham P.L.C. Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2001057039A1 (en) 2000-02-04 2001-08-09 Wyeth Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor
EP1264820A4 (en) 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co amide compounds
US6586469B2 (en) 2000-07-25 2003-07-01 Medpointe Healthcare Inc. Antihistaminic/antitussive compositions
ES2281434T3 (es) 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
CZ2003635A3 (cs) * 2000-09-06 2004-12-15 Ortho Mcneil Pharmaceutical, Inc. Substituovaný pyrazol a jeho použití
US20040267010A1 (en) 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
DE60214138T2 (de) * 2001-02-21 2007-03-29 Janssen Pharmaceutica N.V. Isoxazolin-derivate als antidepressiva
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US20020183519A1 (en) 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
US6559174B2 (en) 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6806380B2 (en) 2001-10-02 2004-10-19 Lexicon Pharmaceuticals, Inc. Modified safe and efficient process for the environmentally friendly synthesis of imidoesters
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
US20030199544A1 (en) 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030199542A1 (en) 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
HRP20020452A2 (en) 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
CA2487679A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
US20050288355A1 (en) 2002-06-20 2005-12-29 Arne Mork Combination therapy wherein a serotonin reuptake inhibitor is used
CA2493637A1 (en) 2002-07-25 2004-02-12 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004014374A1 (en) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004011467A1 (ja) 2002-07-29 2004-02-05 Hokko Chemical Industry Co., Ltd. トリアゾロピリミジン誘導体および農園芸用殺菌剤
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
EP1556360B1 (en) 2002-10-30 2008-01-23 Ciba SC Holding AG Electroluminescent device
JP2006516604A (ja) 2003-01-31 2006-07-06 ファイザー・プロダクツ・インク ５ｈｔ７アンタゴニストおよび逆アゴニスト
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0316128D0 (en) 2003-07-10 2003-08-13 Univ Aston Novel sulfonamide compounds
JP4679517B2 (ja) 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド 薬剤としてのアゼピン誘導体
MXPA06003150A (es) 2003-09-17 2006-08-31 Johnson & Johnson Compuestos heterociclicos fusionados.
AU2004276341B2 (en) * 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
CA2538023A1 (en) 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
WO2005056056A2 (en) 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US20050232986A1 (en) 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20090227562A1 (en) 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
US20060037652A1 (en) 2004-08-23 2006-02-23 Ranco Incorporated Of Delaware Reversing valve assembly with improved pilot valve mounting structure
US20060194837A1 (en) 2004-12-17 2006-08-31 Carruthers Nicholas I Tetrahydroisoquinoline compounds
JP2008546711A (ja) 2005-06-17 2008-12-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｎｓ障害の処置のためのヘキサヒドロ−ピロロ−イソキノリン化合物
ES2314933T3 (es) 2005-06-17 2009-03-16 Janssen Pharmaceutica Nv Compuestos de naftiridina.
KR101353268B1 (ko) 2005-08-04 2014-02-06 얀센 파마슈티카 엔.브이. 세로토닌 수용체 모듈레이터로서의 피리미딘 화합물
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
KR20080109841A (ko) * 2006-03-10 2008-12-17 뉴로젠 코포레이션 피페라지닐 옥소알킬 테트라히드로이소퀴놀린 및 관련유사체
CN101479252B (zh) 2006-05-05 2014-01-29 詹森药业有限公司 用于制备含吡唑的化合物的方法
EP2049473A2 (en) 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
EP2049466A1 (en) 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
CN101511790A (zh) 2006-06-29 2009-08-19 詹森药业有限公司 取代的氨基甲基苯甲酰胺化合物
WO2008064036A1 (en) 2006-11-16 2008-05-29 Janssen Pharmaceutica N.V. Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators

Also Published As

Publication number Publication date
CL2009000943A1 (es) 2009-08-21
JP2007505908A (ja) 2007-03-15
MXPA06003150A (es) 2006-08-31
HK1118550A1 (en) 2009-02-13
EA200801812A1 (ru) 2009-06-30
WO2005040169A2 (en) 2005-05-06
EA010905B1 (ru) 2008-12-30
IL174283A0 (en) 2006-08-01
ES2319539T3 (es) 2009-05-08
KR101151653B1 (ko) 2012-06-28
CR8302A (es) 2008-09-10
PT1668014E (pt) 2009-03-17
US7402680B2 (en) 2008-07-22
AU2004283196B2 (en) 2011-08-25
PL1668014T3 (pl) 2009-06-30
CN103788089A (zh) 2014-05-14
JP5069907B2 (ja) 2012-11-07
BRPI0414541B1 (pt) 2019-02-26
IS8348A (is) 2006-03-09
BRPI0414541A8 (pt) 2019-01-02
CY1109416T1 (el) 2014-08-13
KR20070023633A (ko) 2007-02-28
US20090270370A1 (en) 2009-10-29
DK1668014T3 (da) 2009-04-20
BRPI0414541A (pt) 2006-11-07
ATE420881T1 (de) 2009-01-15
US20110040088A1 (en) 2011-02-17
CA2539426A1 (en) 2005-05-06
SG146683A1 (en) 2008-10-30
CA2539426C (en) 2012-07-10
US7897771B2 (en) 2011-03-01
IL209082A0 (en) 2011-01-31
EA200600433A1 (ru) 2006-08-25
ECSP066436A (es) 2006-09-18
US20050119295A1 (en) 2005-06-02
TW200521123A (en) 2005-07-01
TWI345565B (en) 2011-07-21
IS2756B (is) 2011-10-15
IL174283A (en) 2012-06-28
DE602004019118D1 (de) 2009-03-05
US8618288B2 (en) 2013-12-31
NZ545836A (en) 2009-09-25
SI1668014T1 (sl) 2009-06-30
EP1668014B1 (en) 2009-01-14
US20100016281A1 (en) 2010-01-21
BRPI0414541B8 (pt) 2021-05-25
US7579470B2 (en) 2009-08-25
WO2005040169A3 (en) 2006-03-30
US20080103132A1 (en) 2008-05-01
AU2004283196A1 (en) 2005-05-06
EP1668014A2 (en) 2006-06-14
AR047218A1 (es) 2006-01-11

Similar Documents

Publication Publication Date Title
NI200600094A (es) Compuesto heterociclicos fusionados
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
ECSP077360A (es) Compuestos sulfonamida
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
EA200802213A1 (ru) Способы лечения заболеваний крови
ECSP066355A (es) Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2
ATE461217T1 (de) Glp-1-verbindungen
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
BRPI0614397A2 (pt) compostos de pirimidina como moduladores de receptor de serotonina
ATE409188T1 (de) Naphthyridinverbindungen
GT200300183A (es) Nuevos agonistas ppar-alfa y ppar-gamma
SE0301650D0 (sv) Novel compounds
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
AR032548A1 (es) Metodo y composicion para desinfectar una superficie contaminada con una proteina prion
UA85563C2 (ru) Конденсированные гетероциклические соединения
CR8009A (es) Compuestos benzo[1,2,5] tiadiazoles
ATE498619T1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
ATE404550T1 (de) Chemische verbindungen
DE602004017354D1 (de) Muscarine agonisten als therapeutische verbindungen
UY28599A1 (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
MY145145A (en) Fused pyrazole-containing heterocyclic compounds as serotonin receptor modulators
TW200744607A (en) Pyrimidine compounds as serotonin receptor modulators